Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Evaluating the Efficacy of the Dual Inhibition of Phosphoinositide 3 Kinase (PI3K)/Akt /Mammalian Target Of Rapamycine (mTOR) Signaling Pathway by PF-05212384 (PKI-587) for Patients With Myeloid Neoplasm Secondary to Chemo-radiotherapy (t-AML/MDS) or de Novo Relapsed or Refractory AML.

NCT02438761 is registered in ClinicalTrials.gov with Institut Curie as lead sponsor.

NCT NCT02438761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02438761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Evaluating the Efficacy of the Dual Inhibition of Phosphoinositide 3 Kinase (PI3K)/Akt /Mammalian Target Of Rapamycine (mTOR) Signaling Pathway by PF-05212384 (PKI-587) for Patients With Myeloid Neoplasm Secondary to Chemo-radiotherapy (t-AML/MDS) or de Novo Relapsed or Refractory AML.
Lead sponsor
Institut Curie
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2015
Completion date
April 23, 2018
Enrollment
10 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, in relapse, de novo acute myeloid leukemia at diagnostic, therapy-related acute myeloid leukemia and myelodysplastic syndrome